[1] 郑荣寿, 孙可欣, 张思维,等. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志,2019, 41:19-28.
[2] Jackson R, Psarelli EE, Berhane S, et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular Cancer: a metaanalysis of randomized phase III trials. J Clin Oncol,2017,35: 622-628.
[3] Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol,2017,67: 999-1008.
[4] Kudo M. Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial. Liver Cancer,2018,7:225-234.
[5] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet,2018,391:1163-1173.
[6] Takuji O, Kenji I, Masatoshi K, et al. Safety and efficacy of lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT. ASCO-GI 2019. Poster No. 316.
[7] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet,2017,389:56-66.
[8] Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med,2018,379:54-63.
[9] Kudo M. Ramucirumab as second-line systemic therapy in hepatocellular carcinoma. Liver Cancer,2018,7:305-311.
[10] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol,2018,19: 940-952.
[11] Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol,2019,15:1811-1822.
[12] Ikeda M, Sung MW, Kudo M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol,2018,36: 4076. |
